Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: US FDA Shoots Down Lilly's Baricitinib, Approves Neurocrine's Ingrezza

Apr 14 2017

• By Bridget Silverman

Keeping Track Feature image

Related Content

Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD

Apr 13 2017

Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response

Apr 07 2017

Agile's Phase III Data For Twirla Patch Fall Flat, Raise Doubts On Approval

Jan 05 2017

Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Dec 16 2016

Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid

Jan 22 2017

Ocular Therapeutix Gets Lead Product Back On Track

Feb 23 2017

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

Apr 14 2017

Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval

Oct 29 2016

Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval

Sep 23 2016

Related Companies

Neurocrine Biosciences, Inc.

Eli Lilly and Company

Incyte Corporation

Genentech, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

TherapeuticsMD Inc.

Agile Therapeutics, Inc.

Ocular Therapeutix, Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Approvals Complete Response Letters Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window